Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A List

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)Rogerio C Lilenbaum, James E Herndon, Marcy A List, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancerFred R Rosen, Daniel J Haraf, Merrill S Kies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancerEverett E Vokes, Kerstin Stenson, Fred R Rosen, et al.
Leukemia|October 31, 2015
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesD A Sallman, R Komrokji, C Vaupel, et al.
Blood|August 31, 2006
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitorsTony A Navas, Mani Mohindru, Myka Estes, et al.
Leukemia|October 15, 2015
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosidesA M Zeidan, M A Sekeres, G Garcia-Manero, et al.
Oncogene|April 25, 2012
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionS Wei, X Chen, K McGraw, et al.
Psycho-Oncology|March 5, 2008
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804Electra D Paskett, James E Herndon, Jeannette M Day, et al.
Leukemia|June 13, 2008
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemiaE J Feldman, J Cortes, D J DeAngelo, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)Rogerio C Lilenbaum, James E Herndon, Marcy A List, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancerFred R Rosen, Daniel J Haraf, Merrill S Kies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancerEverett E Vokes, Kerstin Stenson, Fred R Rosen, et al.
Leukemia|October 31, 2015
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesD A Sallman, R Komrokji, C Vaupel, et al.
Blood|August 31, 2006
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitorsTony A Navas, Mani Mohindru, Myka Estes, et al.
Leukemia|October 15, 2015
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosidesA M Zeidan, M A Sekeres, G Garcia-Manero, et al.
Oncogene|April 25, 2012
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionS Wei, X Chen, K McGraw, et al.
Psycho-Oncology|March 5, 2008
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804Electra D Paskett, James E Herndon, Jeannette M Day, et al.
Leukemia|June 13, 2008
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemiaE J Feldman, J Cortes, D J DeAngelo, et al.
Pageof 16